Ono Pharmaceutical Co., Ltd. resolved at the Board meeting on March 5, 2026, to introduce a long-term incentive stock compensation plan equivalent to JPY 20,454 million and 8,398,300 shares for employees of its U.S. subsidiary, Deciphera Pharmaceuticals, Inc.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4528-20260305-01.pdf","jir_short_summary":"Ono Pharmaceutical Co., Ltd. resolved at the Board meeting on March 5, 2026, to introduce a long-term incentive stock compensation plan equivalent to JPY 20,454 million and 8,398,300 shares for employees of its U.S. subsidiary, Deciphera Pharmaceuticals, Inc.","jir_summary":"### Overview of the Introduction of the Long-Term Incentive Stock Compensation Plan\nOno Pharmaceutical Co., Ltd. resolved at the Board of Directors meeting on March 5, 2026, to implement a long-term incentive stock compensation plan (ESOP Trust) for employees of its U.S. subsidiary Deciphera Pharmaceuticals, Inc. The plan aims to enhance employee engagement and increase corporate value over the medium to long term. Under this plan, the ESOP Trust will acquire treasury stock which will be granted to employees, enabling them to benefit economically from potential stock price appreciation. Additionally, voting rights will be exercised in a manner reflecting the employees\u2019 intentions.\n\n### Impact on Shareholders and Future Outlook\nIn conjunction with the introduction of this plan, the Company will dispose of 8,398,300 shares of treasury stock (equivalent to JPY 20,454 million) to the ESOP Trust out of 28,785,143 shares of treasury stock held as of September 30, 2025. The trust period is scheduled from March 23, 2026 to March 31, 2029. Upon the trust\u2019s termination, the Company will decide on either cancelling the remaining shares or continuing the plan. This initiative is expected to heighten employees\u2019 participation awareness in management and contribute to enhancing corporate value.","jir_financial_highlights":"Number of Treasury Stock Disposed: 8,398,300 shares (Unknown)\nAmount of Treasury Stock Disposed: JPY 20,454 million (Unknown)\nTrust Period: March 23, 2026 \u2013 March 31, 2029 (planned) (Unknown)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #LongTermIncentive, #ESOP, #general_ir, #JapaneseStocks","jir_key_figures":"Number of Treasury Stock Disposed: 8,398,300 shares\nAmount of Treasury Stock Disposed: JPY 20,454 million\nTrust Period: March 23, 2026 \u2013 March 31, 2029 (planned)","jir_meta_title":"Ono Pharmaceutical Introduces Long-Term Incentive Stock Compensation Plan Worth JPY 20,454 Million for U.S. Subsidiary Employees","jir_meta_description":"On March 5, 2026, Ono Pharmaceutical Co., Ltd. introduced a long-term incentive stock compensation plan equivalent to 8,398,300 shares and JPY 20,454 million for employees of its U.S. subsidiary Deciphera Pharmaceuticals, aiming to enhance corporate value.","jir_og_title":"Ono Pharmaceutical Introduces Long-Term Incentive Plan for U.S. Subsidiary Employees","jir_og_description":"Ono Pharmaceutical Co., Ltd. has introduced a long-term incentive stock compensation plan worth JPY 20,454 million for employees of its U.S. subsidiary Deciphera Pharmaceuticals.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-33297","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n